Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 13:2:91.
doi: 10.3389/fneur.2011.00091. eCollection 2011.

Treatment of Essential Tremor: Are there Issues We are Overlooking?

Elan D Louis  1
Affiliations

Treatment of Essential Tremor: Are there Issues We are Overlooking?

Elan D Louis. Front Neurol. .

Abstract

Background: Essential tremor (ET) is one of the most common neurological diseases. Although a large number of medications have been tested, there are only two first-line medications, primidone and propranolol, which is a situation that has not changed in approximately 30 years. Several recent reviews have summarized the current pharmacotherapeutic options for ET and the approach to the management of ET patients. Yet there remain a number of important issues, both scientific and clinical, that have not been broached in the literature and that have therapeutic implications.

Objectives: To introduce several clinical and scientific issues that have not formally entered the published literature on the treatment of ET.

Methods: In September 2011, materials for this article were gathered during a literature search of PubMed using the following terms: ET, clinical, clinical trial, treatment, medications, therapeutics. English-language articles were selected for further review.

Results: The paper focuses on several topics that have received scant or no discussion in the published literature on ET therapeutics. These topics are as follows: the nature of the underlying disease pathophysiology, the presence of pathological heterogeneity, the complexity of cellular and neurochemical changes which may be underlying this disorder, the presence of clinical heterogeneity, the selection of treatment endpoints, the effects of diagnostic uncertainty, the presence of cognitive and psychiatric features in ET, the identification of possible modifiable risk factors, and the absence of any neuroprotective therapies.

Conclusion: The author has identified several topics that have received scant or no discussion in the published literature on ET therapeutics. Further discussion of the issues raised here may lead to improvements in clinical trial methodologies as well as facilitate the development of fresh approaches to pharmacotherapy.

Keywords: clinical; essential tremor; pharmacology; treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Apaydin H., Ahlskog J. E., Parisi J. E., Boeve B. F., Dickson D. W. (2002). Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59, 102–11210.1001/archneur.59.1.102 - DOI - PubMed
    1. Arima H. (2009). Blood pressure-lowering treatment for primary and secondary prevention of different types of stroke. Expert Rev. Cardiovasc. Ther. 7, 627–63610.1586/erc.09.26 - DOI - PubMed
    1. Axelrad J. E., Louis E. D., Honig L. S., Flores I., Ross G. W., Pahwa R., Lyons K. E., Faust P. L., Vonsattel J. P. (2008). Reduced Purkinje cell number in essential tremor: a postmortem study. Arch. Neurol. 65, 101–10710.1001/archneurol.2007.8 - DOI - PMC - PubMed
    1. Bain P., Brin M., Deuschl G., Elble R., Jankovic J., Findley L., Koller W. C., Pahwa R. (2000). Criteria for the diagnosis of essential tremor. Neurology 54, S7. - PubMed
    1. Bain P. G., Findley L. J., Thompson P. D., Gresty M. A., Rothwell J. C., Harding A. E., Marsden C. D. (1994). A study of hereditary essential tremor. Brain 117(Pt 4), 805–82410.1093/brain/117.4.805 - DOI - PubMed

LinkOut - more resources